These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
239 related articles for article (PubMed ID: 11847402)
21. Characterization of myocardial infarction as an end point in two large trials of acute coronary syndromes. Mahaffey KW; Roe MT; Kilaru R; French JK; Alexander JH; Berdan LG; Van De Werf F; Simoons ML; Weaver WD; White HD; Lincoff AM; Kleiman NS; Topol EJ; Harrington RA Am J Cardiol; 2005 Jun; 95(12):1404-8. PubMed ID: 15950560 [TBL] [Abstract][Full Text] [Related]
23. Effect of platelet glycoprotein IIb/IIIa receptor blockade with tirofiban on adverse cardiac events in women with unstable angina/non-ST-elevation myocardial infarction (PRISM-PLUS Study). Huynh T; Theroux P; Snapinn S; Wan Y; Am Heart J; 2003 Oct; 146(4):668-73. PubMed ID: 14564321 [TBL] [Abstract][Full Text] [Related]
24. Primary percutaneous coronary intervention in acute myocardial infarction. Singh KP; Harrington RA Med Clin North Am; 2007 Jul; 91(4):639-55; x-xi. PubMed ID: 17640540 [TBL] [Abstract][Full Text] [Related]
25. Implications of upstream glycoprotein IIb/IIIa inhibition and coronary artery stenting in the invasive management of unstable angina/non-ST-elevation myocardial infarction: a comparison of the Thrombolysis In Myocardial Infarction (TIMI) IIIB trial and the Treat angina with Aggrastat and determine Cost of Therapy with Invasive or Conservative Strategy (TACTICS)-TIMI 18 trial. Sabatine MS; Morrow DA; Giugliano RP; Murphy SA; Demopoulos LA; DiBattiste PM; Weintraub WS; McCabe CH; Antman EM; Cannon CP; Braunwald E Circulation; 2004 Feb; 109(7):874-80. PubMed ID: 14757697 [TBL] [Abstract][Full Text] [Related]
27. The evolving role of glycoprotein IIb/IIIa inhibitor therapy in contemporary care of acute coronary syndrome patients. Tricoci P; Peterson ED J Interv Cardiol; 2006 Oct; 19(5):449-55. PubMed ID: 17020570 [TBL] [Abstract][Full Text] [Related]
28. Examining treatment of ST-elevation myocardial infarction: the importance of early intervention. Lamas GA; Escolar E; Faxon DP J Cardiovasc Pharmacol Ther; 2010 Mar; 15(1):6-16. PubMed ID: 20061507 [TBL] [Abstract][Full Text] [Related]
29. Glycoprotein IIb/IIIa receptor antagonists: are we ignoring the evidence. Singh S; Gopal AK; Bahl VK Indian Heart J; 2005; 57(3):201-9. PubMed ID: 16196176 [No Abstract] [Full Text] [Related]
30. Facilitated angioplasty with combo therapy among patients with ST-segment elevation myocardial infarction: a meta-analysis of randomized trials. De Luca G; Marino P Am J Emerg Med; 2009 Jul; 27(6):683-90. PubMed ID: 19751625 [TBL] [Abstract][Full Text] [Related]
31. Antithrombotic therapy and the transition to the catheterization laboratory in UA/NSTEMI. Ferguson JJ; Wilson JM; Diez J Minerva Cardioangiol; 2007 Oct; 55(5):529-56. PubMed ID: 17912162 [TBL] [Abstract][Full Text] [Related]
32. Facilitated reperfusion with prehospital glycoprotein IIb/IIIa inhibition: predictors of complete ST-segment resolution before primary percutaneous coronary intervention in the On-TIME 2 trial: correlates of reperfusion before primary PCI. Heestermans T; Suryapranata H; ten Berg JM; Mosterd A; Gosselink AT; Kochman W; Dill T; van Houwelingen G; Kolkman E; van Werkum JW; Zijlstra F; Hamm C; van 't Hof AW J Electrocardiol; 2011; 44(1):42-8. PubMed ID: 21168000 [TBL] [Abstract][Full Text] [Related]
33. The glycoprotein IIb/IIIa inhibitor wars: an update. Berger PB J Am Coll Cardiol; 2010 Aug; 56(6):476-8. PubMed ID: 20670757 [No Abstract] [Full Text] [Related]
34. Facilitation of thrombolysis in acute myocardial infarction. Gambhir DS Indian Heart J; 1999; 51(5):486-8. PubMed ID: 10721636 [No Abstract] [Full Text] [Related]
35. Combination fibrinolytic therapy and platelet glycoprotein IIb/IIIa receptor blockade in acute myocardial infarction: an emerging solution for reperfusion. Kaplan AL; Goldmann B; Ohman EM J Emerg Med; 1999; 17(3):589-95. PubMed ID: 10338261 [No Abstract] [Full Text] [Related]
36. Reperfusion therapy for acute myocardial infarction with fibrinolytic therapy or combination reduced fibrinolytic therapy and platelet glycoprotein IIb/IIIa inhibition: the GUSTO V randomised trial. Pereira H; Rev Port Cardiol; 2001 Jun; 20(6):687-8. PubMed ID: 11525077 [No Abstract] [Full Text] [Related]
37. Optimal management of acute coronary syndromes. Hillis LD; Lange RA N Engl J Med; 2009 May; 360(21):2237-40. PubMed ID: 19458369 [No Abstract] [Full Text] [Related]
38. Fibrinolysis and stenting in acute myocardial infarction: newlyweds destined for a 'ménage à trois'? McFadden EP Eur Heart J; 2001 Jul; 22(13):1067-9. PubMed ID: 11428845 [No Abstract] [Full Text] [Related]
39. Administration of glycoprotein IIb-IIIa inhibitors in patients with ST-segment elevation myocardial infarction. Dobesh PP; Kasiar JB Pharmacotherapy; 2002 Jul; 22(7):864-88. PubMed ID: 12126220 [TBL] [Abstract][Full Text] [Related]
40. Pharmaco-invasive vs. facilitated percutaneous coronary intervention strategies for ST-segment-elevation acute myocardial infarction patients in the new ESC Guidelines. Tofield A Eur Heart J; 2009 Dec; 30(23):2817. PubMed ID: 19952008 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]